To book an appointment, please call Dr. Tabatabai’s secretary at (713) 807-4271 or book online using the button below.
|Areas of Expertise|
|Board Certification||American Board of Internal Medicine, 2012|
Endocrinology, Diabetes & Metabolism, 2014
|Hospital Affiliation||Houston Methodist Hospital|
Laila S. Tabatabai, M.D. began seeing patients at MCH August, 2021. She is an Associate Professor of Clinical Medicine in the Division of Endocrinology, Academic Institute at Houston Methodist Hospital and Weill Cornell Medical College. She received her medical degree with distinction in research at Albany Medical College in Albany, New York. Her postdoctoral training included an internship and residency in internal medicine at the University of Maryland Medical Center in Baltimore and a fellowship in endocrinology at Johns Hopkins Hospital in Baltimore.
Dr. Tabatabai is a member of the National Osteoporosis Foundation Ambassadors Leadership Council. She previously was the Program Director of the Houston Methodist Endocrinology Fellowship program. Her didactic teaching included a focus on the management of metabolic bone disease and osteoporosis and has presented at national meetings including the American Association of Clinical Endocrinologists (AACE), Endocrine Society, American Society of Bone and Mineral Research and the Endocrine Nurses Society Symposium.
As the former Director of the Houston Methodist Hospital (HMH) Fracture Liaison Service, she focused on providing education to reduce fracture risk and coordinating treatment programs for fracture patients. Dr. Tabatabai has been the recipient of numerous research grants in the area of osteoporosis. She has authored peer-reviewed publications appearing in the Journal of Clinical Endocrinology and Metabolism and in Endocrine Practice as well as book chapters and abstracts. She is considered an expert in the field of anabolic agents for treatment of fragility fractures in high-risk osteoporosis patients.
Dr. Tabatabai is the Principle Investigator for the Disease Monitoring Program (UX023-CL401) for burosumab, an anti-FGF23 monoclonal antibody which corrects phosphate homeostasis in individuals with X-linked hypophosphatemic rickets. She has chaired the Endocrine Society’s CME and MOC-certified educational program on hypophosphatemia.